Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306677 | 0.85 | RAB9A (0.54) | RAB9AHDAC1DRD2DRD3NPC1 | |
| SCHEMBL13926363 | 0.85 | RAB9A (0.50) | RAB9AHDAC1DRD2DRD3NPC1 | |
| SCHEMBL17233735 | 0.85 | RAB9A (0.50) | RAB9AHDAC1DRD2DRD3NPC1 | |
| SCHEMBL18127988 | 0.84 | RAB9A (0.47) | RAB9AHDAC1NPC1MEN1KMT2A | |
| SCHEMBL17993496 | 0.81 | RAB9A (0.50) | RAB9AHDAC1DRD2DRD3NPC1 | |
| SCHEMBL14817504 | 0.81 | RAB9A (0.47) | RAB9AHDAC1DRD2DRD3NPC1 | |
| SCHEMBL17993541 | 0.80 | RAB9A (0.49) | RAB9AHDAC1DRD2DRD3NPC1 | |
| SCHEMBL5097841 | 0.80 | RAB9A (0.53) | RAB9AHDAC1DRD2DRD3NPC1 | |
| SCHEMBL18127983 | 0.78 | MAPT (0.45) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL26933827 | 0.78 | NOTUM (0.40) | RAB9AHDAC1NPC1NOTUMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617257-B2 | Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2017-04-11 | — | — | US | claimed |
| EP-2593462-B1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS C-MET TYROSINE KINASE INHIBITORS | BETTA PHARMACEUTICALS CO LTD (CN) | 2016-09-07 | — | — | EP | claimed |
| US-9242991-B2 | Substituted fused heterocycles as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-01-26 | — | — | US | claimed |
| US-20150315210-A1 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2015-11-05 | — | — | US | claimed |
| EP-2867223-A1 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | Betta Pharmaceuticals Co., Ltd. (CN) | 2015-05-06 | — | — | EP | claimed |
| WO-2014000713-A1 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | ZHEJIANG BETA PHARMA INCORPORATION (CN) | 2014-01-03 | — | — | WO | claimed |
| EP-2593462-A1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | Zhejiang Beta Pharma Inc. (CN) | 2013-05-22 | — | — | EP | claimed |
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2013-05-16 | — | — | US | claimed |
| CN-103052641-A | Novel fused heterocyclic derivatives as c-Met inhibitors | ZHEJIANG BETA PHARMA INC | 2013-04-17 | — | — | CN | claimed |
| WO-2012006960-A1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | ZHEJIANG BETA PHARMA INC. (CN) | 2012-01-19 | — | — | WO | claimed |
| EP-2867223-B1 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | BETTA PHARMACEUTICALS CO LTD (CN) | 2018-09-05 | — | — | EP | disclosed |
| US-9617257-B2 | Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2017-04-11 | — | — | US | disclosed |
| CN-103052641-B | Novel fused heterocyclic derivatives as c-Met inhibitors | BETTA PHARMACEUTICALS Co.,Ltd. (CN) | 2016-11-30 | — | — | CN | disclosed |
| EP-2593462-B1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS C-MET TYROSINE KINASE INHIBITORS | BETTA PHARMACEUTICALS CO LTD (CN) | 2016-09-07 | — | — | EP | disclosed |
| US-9242991-B2 | Substituted fused heterocycles as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-01-26 | — | — | US | disclosed |
| EP-2593462-A1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | Zhejiang Beta Pharma Inc. (CN) | 2013-05-22 | — | — | EP | disclosed |
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2013-05-16 | — | — | US | disclosed |
| CN-103052641-A | Novel fused heterocyclic derivatives as c-Met inhibitors | ZHEJIANG BETA PHARMA INC | 2013-04-17 | — | — | CN | disclosed |
| WO-2012047017-A2 | 2,3-DIHYDRO-ISOINDOL-1-ONE DERIVATIVE AND A COMPOSITION COMPRISING THE SAME | 크리스탈지노믹스(주) (KR) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012006960-A1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | ZHEJIANG BETA PHARMA INC. (CN) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315210-A1 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | MET, ABL1, ROS1 | RAB9A 1372/4885HDAC1 3120/4885DRD2 4109/4885 |
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | MET, RET, ABL1 | RAB9A 805/4885HDAC1 3366/4885DRD2 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.